Vivus, Inc.

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

The Centers for Medicare and Medicaid Services is leaning toward changing the drug classification standard for private insurance plans serving the individual and small group markets in a way that coul

Long-overdue updates to a US Food and Drug Administration guidance on weight management drugs could be a key tool to convince Medicare that it can cover anti-obesity drugs. The FDA is working on an up

Novo Nordisk A/S 's high-growth obesity drugs – Wegovy (semaglutide) and Saxenda (liraglutide) – do not meet commonly used US cost effectiveness benchmarks at current prices, according to draft eviden